X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs PANACEA BIOTECH - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. PANACEA BIOTECH FRESENIUS KABI ONCO./
PANACEA BIOTECH
 
P/E (TTM) x 22.1 144.0 15.4% View Chart
P/BV x 3.1 3.2 97.3% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 FRESENIUS KABI ONCO.   PANACEA BIOTECH
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
PANACEA BIOTECH
Mar-14
FRESENIUS KABI ONCO./
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs176149 118.4%   
Low Rs7982 95.4%   
Sales per share (Unadj.) Rs37.784.1 44.8%  
Earnings per share (Unadj.) Rs5.1-18.3 -27.8%  
Cash flow per share (Unadj.) Rs6.7-6.7 -100.4%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs42.583.7 50.8%  
Shares outstanding (eoy) m158.2361.25 258.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.41.4 246.0%   
Avg P/E ratio x25.0-6.3 -396.0%  
P/CF ratio (eoy) x18.9-17.2 -109.8%  
Price / Book Value ratio x3.01.4 216.8%  
Dividend payout %00-   
Avg Mkt Cap Rs m20,1357,074 284.6%   
No. of employees `0001.22.8 41.9%   
Total wages/salary Rs m7031,449 48.5%   
Avg. sales/employee Rs Th5,176.21,874.1 276.2%   
Avg. wages/employee Rs Th610.4527.0 115.8%   
Avg. net profit/employee Rs Th699.6-407.7 -171.6%   
INCOME DATA
Net Sales Rs m5,9635,154 115.7%  
Other income Rs m18100 18.0%   
Total revenues Rs m5,9815,254 113.8%   
Gross profit Rs m1,430-766 -186.6%  
Depreciation Rs m258711 36.3%   
Interest Rs m-261,503 -1.7%   
Profit before tax Rs m1,216-2,881 -42.2%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 0.0%   
Extraordinary Inc (Exp) Rs m-681,771 -3.8%   
Tax Rs m34217 2,036.9%   
Profit after tax Rs m806-1,121 -71.9%  
Gross profit margin %24.0-14.9 -161.3%  
Effective tax rate %28.1-0.6 -4,824.3%   
Net profit margin %13.5-21.8 -62.1%  
BALANCE SHEET DATA
Current assets Rs m5,1023,810 133.9%   
Current liabilities Rs m2,3858,365 28.5%   
Net working cap to sales %45.6-88.4 -51.5%  
Current ratio x2.10.5 469.5%  
Inventory Days Days150156 96.4%  
Debtors Days Days11367 168.5%  
Net fixed assets Rs m5,14814,480 35.6%   
Share capital Rs m15861 258.1%   
"Free" reserves Rs m6,556903 725.9%   
Net worth Rs m6,7325,127 131.3%   
Long term debt Rs m9525,832 16.3%   
Total assets Rs m10,38819,433 53.5%  
Interest coverage x-45.8-0.9 4,994.8%   
Debt to equity ratio x0.11.1 12.4%  
Sales to assets ratio x0.60.3 216.5%   
Return on assets %7.52.0 382.2%  
Return on equity %12.0-21.9 -54.7%  
Return on capital %14.63.6 401.6%  
Exports to sales %74.524.5 303.7%   
Imports to sales %24.810.2 243.3%   
Exports (fob) Rs m4,4411,264 351.4%   
Imports (cif) Rs m1,477525 281.5%   
Fx inflow Rs m5,2981,539 344.2%   
Fx outflow Rs m1,772942 188.1%   
Net fx Rs m3,525597 590.3%   
CASH FLOW
From Operations Rs m1,274599 212.6%  
From Investments Rs m-1,204-438 275.0%  
From Financial Activity Rs m-196-303 64.8%  
Net Cashflow Rs m-126-141 89.4%  

Share Holding

Indian Promoters % 0.0 74.5 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.6 50.0%  
FIIs % 9.6 1.3 738.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 23.6 38.6%  
Shareholders   42,599 10,259 415.2%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   TORRENT PHARMA  NATCO PHARMA  ELDER PHARMA  PFIZER  ALKEM LABORATORIES  

Compare FRESENIUS KABI ONCO. With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Power Stocks Top Losers(01:30 pm)

After opening the day in green share markets in India witnessed choppy trading activity and are presently trading above the dotted line.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

The ONLY Thing You Need to Know About Bitcoin(The 5 Minute Wrapup)

Jan 6, 2018

You either want it or you want to get as far away from it as possible - but Bitcoin is just the noise masking the REAL opportunity. Read about it here...

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. 5-YR ANALYSIS

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS